Document is current
Any future updates will be listed below
-
Authors
Strelez, Carly
Battaglin, Francesca
Perez, Rachel
Yang, Yan
Cherry, Christopher
Millstein, Joshua https://orcid.org/0000-0001-7961-8943
Yoon, Ah Young
Chlystek, John S.
Canfield, Ethan
Haliday, Bethany
Shah, Curran https://orcid.org/0000-0001-5031-9501
Ghaffarian, Kimya
Soni, Shivani https://orcid.org/0000-0002-6368-4177
Jiang, Hannah
Lau, Roy
Schatz, Aaron
Zhou, Yuyuan https://orcid.org/0000-0002-8317-4115
Mulkerin, Daniel
Ou, Fang-Shu https://orcid.org/0000-0003-1267-8735
Venook, Alan P.
Innocenti, Federico
Neman, Josh
Katz, Jonathan E.
Lenz, Heinz-Josef https://orcid.org/0000-0003-2178-9568
Mumenthaler, Shannon M.
-
Funding
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Cancer Institute (UM1CA186717, P30CA014089, U10CA180821, U10CA180882, U10CA180888)
- License Information
-
More Information
Article History
Received: 10 April 2025
Revised: 15 July 2025
Accepted: 11 August 2025
First Online: 24 August 2025
Change Date: 6 October 2025
Change Type: Update
Change Details: Acknowledgements has been updated.
Competing interests
: F. Innocenti is a holder of patents on genetic prediction of neutropenia, hypertension, and proteinuria in cancer patients treated with anti-cancer agents. He is an employee of BeOne and has stocks in both AbbVie and BeOne. All other authors declare that they have no competing interests.
